Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Guanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 6/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL663745 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL5372452 | 0.95 | KDM4E (0.51) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL15948930 | 0.94 | KDM4E (0.50) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL4658042 | 0.92 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL5259 | 0.92 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL101892 | 0.91 | KDM4E (0.48) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL27542045 | 0.90 | HSD17B10 (0.56) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL865492 | 0.90 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL2895087 | 0.90 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL21611717 | 0.90 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 969 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596713-A1 | DNA WITH ENHANCED RESISTANCE AGAINST EXONUCLEASES AND METHODS FOR THE PRODUCTION THEREOF | 4basebio UK Ltd (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2024250923-A1 | CHEMICALLY MODIFIED NUCLEOSIDE, CHEMICALLY MODIFIED NUCLEOSIDE TRIPHOSPHATE AND USE THEREOF | 中国科学院深圳先进技术研究院 | 2024-12-12 | — | — | WO | claimed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | claimed |
| EP-4146285-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| EP-4087611-A1 | SHP2 INHIBITOR DOSING AND METHODS OF TREATING CANCER | Revolution Medicines, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| CN-115052635-A | Circular RNA compositions and methods | 奥纳治疗公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114929279-A | Methods of administering SHP2 inhibitors and treating cancer | 锐新医药公司 | 2022-08-19 | — | — | CN | claimed |
| EP-3920976-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | claimed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | claimed |
| US-20100317005-A1 | Modified Nucleotides and Methods for Making and Use Same | Life Technologies Corporation (US) | 2010-12-16 | — | — | US | claimed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | claimed |
| US-20080020994-A1 | G proteins in tumor growth and angiogenesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-20060160723-A1 | biodrug as antilipolytic agents for treating mammal to a weight reduction or reduction in obesity | ASTON UNIVERSITY (GB) | 2006-07-20 | — | — | US | claimed |
| EP-1082344-B1 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF | TISDALE MICHAEL JOHN (GB) | 2003-03-19 | — | — | EP | claimed |
| EP-1082344-A2 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF | Tisdale, Michael John (GB) | 2001-03-14 | — | — | EP | claimed |
| EP-1032700-A1 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | New York Medical College (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999062939-A2 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF | TISDALE MICHAEL JOHN (GB) | 1999-12-09 | — | — | WO | claimed |
| WO-1999006592-A9 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | NEW YORK MEDICAL COLLEGE (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999006592-A1 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | NEW YORK MEDICAL COLLEGE (US) | 1999-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | KDM4E 971/4885ALDH1A1 1338/4885LMNA 1447/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | KDM4E 3990/4885ALDH1A1 4484/4885LMNA 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.